MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes. - Wikidata - wikimedia - TriplyDB

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.

http://www.wikidata.org/entity/Q37739020

about

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.

http://www.wikidata.org/entity/Q37739020

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

MDS disease characteristics, n ...... stem cell transplant outcomes.

@en

MDS disease characteristics, n ...... stem cell transplant outcomes.

@nl

type

label

MDS disease characteristics, n ...... stem cell transplant outcomes.

@en

MDS disease characteristics, n ...... stem cell transplant outcomes.

@nl

prefLabel

MDS disease characteristics, n ...... stem cell transplant outcomes.

@en

MDS disease characteristics, n ...... stem cell transplant outcomes.

@nl

P1433

Q37739020-D1475D9A-8CFF-42F6-9545-1D60769A1827

P1476

Q37739020-19CFB168-898B-4B84-AC23-10F15591157F

P2093

Q37739020-064B5B2D-6625-4C4C-BAD3-3D7748962CB2

Q37739020-2CC160A0-1967-4815-B401-CCFD0F35063F

Q37739020-4F724D30-2273-4AC4-B721-11177CC34A8B

Q37739020-69B4758C-16E7-4F96-8A1F-E377199D33FA

Q37739020-98352B4E-FDB0-4C3A-8DEE-3994803DF736

Q37739020-A863AEA3-D809-4FA5-BCFC-6FC99BDB3AA2

Q37739020-C9F3118D-20D3-471D-92D9-2C00844C1FAB

Q37739020-D3B55A05-44EA-49B7-8079-0DE0EECBE0FF

P2860

Q37739020-323F5155-09E9-443B-8CBC-F4FDC55935EF

Q37739020-36EFAF6A-DE14-431F-915D-FD81054825E5

Q37739020-3836C1A3-5C28-44F1-90D4-1272848DEC64

Q37739020-3DBB1399-6C80-460A-A527-E3971624BFD5

Q37739020-4958BBDD-C8DB-486C-A754-A9165C6389B6

Q37739020-5E6DC1BA-7E4B-472B-9C1C-BAA037E54277

Q37739020-84B95C41-8056-4A42-8E76-9EDF1F91B1FF

Q37739020-86D413E0-A6C7-4E08-90DE-393D8000796E

Q37739020-92027A96-4514-470E-B722-D1E1083E3953

Q37739020-99ECCBBF-6B57-4F7B-B18F-D70C8DA0A9C9

P2888

Q37739020-9EBFBC44-F8CD-487F-B1C2-FCE20C18415D

P304

Q37739020-0CBF31A1-330F-4820-A2BE-32832A2E53D8

P31

Q37739020-95321BC9-42DC-43FC-9C95-EAC0FD5F3004

P356

Q37739020-72C2A831-5DB9-4C33-AC1C-7ED6FE77C756

P407

Q37739020-0D278249-F277-4F08-91F3-A685C0A3E597

P433

Q37739020-D12A86A7-812B-4CF5-8BC4-2C6F832774D8

P478

Q37739020-17329DB7-F1D1-4C26-BCC1-422A28C60241

P577

Q37739020-FC9DEB07-EED2-4CEB-8035-8190E29DBC6A

P698

Q37739020-5792DD4F-2CD3-4881-8FB1-AB11B599D028

P932

Q37739020-003C04B9-D88F-4BE6-8278-013E014A2EF2

P356

P1433

Bone Marrow Transplantation

P1476

MDS disease characteristics, n ...... stem cell transplant outcomes.

@en

P2093

B Trottier

http://www.w3.org/2001/XMLSchema#string

C Brunstein

http://www.w3.org/2001/XMLSchema#string

C Ustun

http://www.w3.org/2001/XMLSchema#string

E D Warlick

http://www.w3.org/2001/XMLSchema#string

H Pourhassan

http://www.w3.org/2001/XMLSchema#string

M Dolan

http://www.w3.org/2001/XMLSchema#string

N Bejanyan

http://www.w3.org/2001/XMLSchema#string

T DeFor

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Defining the intensity of conditioning regimens: working definitions

Nonparametric Estimation from Incomplete Observations

International scoring system for evaluating prognosis in myelodysplastic syndromes

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Revised international prognostic scoring system for myelodysplastic syndromes.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

P2888

P304

532-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2016.303

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27941767

http://www.w3.org/2001/XMLSchema#string

P932

5382091

http://www.w3.org/2001/XMLSchema#string